Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells (Q40135808)

17 September 2017

title

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells (English)

1 reference

17 September 2017

Barbara Bröker

7

0 references

Uwe Völker

object named as

Uwe Völker

8

0 references

author name string

Jürgen Sonnemann

1

1 reference

17 September 2017

Linn Dreyer

2

1 reference

17 September 2017

Maite Hartwig

3

1 reference

17 September 2017

Chithra D Palani

4

1 reference

17 September 2017

Le Thi Thu Hong

5

1 reference

17 September 2017

Ulrike Klier

6

1 reference

17 September 2017

James F Beck

9

1 reference

17 September 2017

publication date

8 May 2007

1 reference

Journal of Cancer Research and Clinical Oncology

17 September 2017

published in

1 reference

17 September 2017

volume

133

1 reference

17 September 2017

issue

11

1 reference

17 September 2017

page(s)

847-858

1 reference

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

17 September 2017

cites work

1 reference

12 December 2020

Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.

1 reference

12 December 2020

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

12 December 2020

Antitumor effects of histone deacetylase inhibitor on Ewing's family tumors

1 reference

12 December 2020

Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines

1 reference

12 December 2020

Clinical development of histone deacetylase inhibitors as anticancer agents

1 reference

12 December 2020

Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia

1 reference

12 December 2020

Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy

1 reference

12 December 2020

Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation

1 reference

12 December 2020

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

1 reference

12 December 2020

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo

1 reference

12 December 2020

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

1 reference

12 December 2020

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

1 reference

12 December 2020

Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.

1 reference

12 December 2020

Ewing's sarcoma family of tumors: current management

1 reference

12 December 2020

HDAC inhibitors: Double edge sword for TRAIL cancer therapy?

1 reference

12 December 2020

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients

1 reference

12 December 2020

Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

1 reference

12 December 2020

Histone deacetylase inhibitors: discovery and development as anticancer agents

1 reference

12 December 2020

Many cuts to ruin: a comprehensive update of caspase substrates

1 reference

12 December 2020

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

12 December 2020

Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

1 reference

12 December 2020

Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells

1 reference

12 December 2020

Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

1 reference

12 December 2020

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

1 reference

12 December 2020

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

12 December 2020

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

1 reference

12 December 2020

Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death

1 reference

12 December 2020

Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia

1 reference

12 December 2020

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells

1 reference

12 December 2020

Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).

1 reference

12 December 2020

Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein

1 reference

12 December 2020

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma

1 reference

12 December 2020

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

1 reference

12 December 2020

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein

1 reference

12 December 2020

Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells

1 reference

12 December 2020

Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.

1 reference

12 December 2020

Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).

1 reference

12 December 2020

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

1 reference

12 December 2020

Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.

1 reference

12 December 2020

The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells

1 reference

12 December 2020

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

1 reference

12 December 2020

Apo2L/TRAIL and its death and decoy receptors

1 reference

12 December 2020

Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines

1 reference

12 December 2020

Apoptosis: a link between cancer genetics and chemotherapy

1 reference

12 December 2020

10.1007/S00432-007-0227-8

Identifiers

DOI

1 reference

17 September 2017

1 reference